Bank Ozk (NASDAQ:OZK) released its quarterly earnings results on Thursday. The company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.87 by ($0.01), Briefing.com reports. The company had revenue of $251.14 million for the quarter, compared to analyst estimates of $253.45 million. Bank Ozk had a net margin of 32.47% and a return on equity of 10.88%.

NASDAQ:OZK opened at $29.30 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 0.96 and a quick ratio of 0.96. The company has a market cap of $3.78 billion, a PE ratio of 9.18, a PEG ratio of 0.70 and a beta of 1.85. The business has a 50 day moving average of $29.68. Bank Ozk has a 12 month low of $21.02 and a 12 month high of $42.74.

The business also recently declared a quarterly dividend, which was paid on Friday, July 19th. Investors of record on Friday, July 12th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date of this dividend was Thursday, July 11th. This is a boost from Bank Ozk’s previous quarterly dividend of $0.23. Bank Ozk’s payout ratio is 29.63%.

Several large investors have recently bought and sold shares of the stock. QV Investors Inc. bought a new stake in shares of Bank Ozk in the 2nd quarter worth approximately $4,774,000. Copeland Capital Management LLC raised its holdings in shares of Bank Ozk by 46.6% in the 2nd quarter. Copeland Capital Management LLC now owns 922,363 shares of the company’s stock worth $27,754,000 after purchasing an additional 293,302 shares during the period. Commonwealth Equity Services LLC raised its holdings in shares of Bank Ozk by 21.2% in the 2nd quarter. Commonwealth Equity Services LLC now owns 9,858 shares of the company’s stock worth $296,000 after purchasing an additional 1,724 shares during the period. Oakbrook Investments LLC bought a new stake in shares of Bank Ozk in the 2nd quarter worth approximately $406,000. Finally, Gradient Investments LLC bought a new stake in shares of Bank Ozk in the 2nd quarter worth approximately $46,000. 83.45% of the stock is currently owned by institutional investors.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Stephens assumed coverage on Slack in a research note on Thursday, July 11th. They issued an “overweight” rating and a $43.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $32.55.

Bank Ozk Company Profile

Bank OZK provides retail and commercial banking services to businesses, individuals, and non-profit and governmental entities. The company accepts non-interest bearing checking, interest bearing transaction, business sweep, savings, money market, individual retirement, and other accounts, as well as time deposits.

Featured Article: Intrinsic Value

Earnings History for Bank Ozk (NASDAQ:OZK)

Receive News & Ratings for Bank Ozk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bank Ozk and related companies with MarketBeat.com's FREE daily email newsletter.